Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05074420 · ClinicalTrials.gov registry record · Phase 3
A Study of Baricitinib (LY3009104) in Children With COVID-19
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 6
- Enrollment target
NCT05074420 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 6 participants.
The verdict
NCT05074420, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.
Interventions
- DRUG Baricitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-12-21 |
| Est. Completion | 2024-11-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05074420
The ClinicalTrials.gov registry entry for NCT05074420 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Baricitinib is the first listed.
NCT05074420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05074420 about?
NCT05074420 is a clinical study titled "A Study of Baricitinib (LY3009104) in Children With COVID-19". The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.
What is the current status of trial NCT05074420?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 6 participants. The study started on 2021-12-21. Estimated completion is 2024-11-04.
What interventions are being tested in trial NCT05074420?
The interventions under investigation include: Baricitinib (DRUG).
Who is sponsoring clinical trial NCT05074420?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.